Zai Lab (ZLAB) Preferred Stock Liabilities (2016)
Zai Lab (ZLAB) posted quarterly Preferred Stock Liabilities of $134.5 million for Q4 2016.
Zai Lab (ZLAB) Preferred Stock Liabilities (2016) Analysis & Trends
Zai Lab (ZLAB) has reported Preferred Stock Liabilities for 1 consecutive years, with $134.5 million the latest figure, recorded in Q4 2016.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $134.5 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $134.5 million (changed N/A YoY) and the FY2016 annual result came in at $134.5 million, changed N/A from the prior year.
- Preferred Stock Liabilities held at $134.5 million in Q4 2016 per ZLAB's latest filing.
- Over the last five years, Preferred Stock Liabilities for ZLAB reached as high as $134.5 million in Q4 2016 and fell as low as $134.5 million in Q4 2016.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Zai Lab | 22.02 Bn | 22.02 Bn | 61.30 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | 134.51 Mn |